ArticleJournal of the Pediatric Orthopaedic Society of North America2026
Treatment and Management of Osteofibrous Dysplasia Like Adamantinoma - A Single Institution Experience.
Article in Journal of the Pediatric Orthopaedic Society of North America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteofibrous dysplasia (OFD) is a benign lesion that affects long bones in children. Adamantinoma (ADA) is a rare malignancy. A new entity known as "differentiated" adamantinoma or OFD-like ADA (OFDLA), has emerged. We examined the clinical outcomes of patients with these conditions. Methods: A single-institution chart review of 59 patients from 1958 to 2016 was performed. Patient and treatment characteristics were compared across tumor types. Logistic regression was used to assess differences in outcomes including receipt of surgery, local recurrence, and development of metastatic disease. Results: A total of 43 patients were diagnosed with OFD, 17 were treated surgically, and there were 6 local recurrences. Out of the 9 OFDLA patients, 7 were treated surgically, and there were 4 local recurrences. All 5 patients with ADA were treated with wide excision, there was one local recurrence treated with re-excision, and one patient developed metastatic disease after treatment. The OFDLA patients were more than four times as likely to undergo surgery compared to OFD patients (OR = 4.5, 95% CI = 1.1-26.6, Conclusions: OFD and OFDLA patients can be managed conservatively, with surgical intervention reserved for those with radiographically extensive or symptomatic lesions. ADA should continue to be treated with wide local resection. Key Concepts: (1)OFD, OFDLA, and ADA exist in a spectrum of disease, and they are rare pathological entities.(2)Historically, OFDLA and ADA were treated like true malignancies, with wide resection and reconstruction. Our data suggest that OFD and OFDLA patients can be managed conservatively, with surgical intervention reserved for those with radiographically extensive or symptomatic lesions.(3)ADA is a low-grade malignant bone tumor with indications for wide resection. Level of Evidence: III, Retrospective Cohort Study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.